Teva Pharmaceutical Industries Ltd. $TEVA Holdings Reduced by Ion Asset Management Ltd.

Ion Asset Management Ltd. lowered its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 85.6% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 5,510,000 shares of the company’s stock after selling 32,837,875 shares during the period. Teva Pharmaceutical Industries comprises about 12.2% of Ion Asset Management Ltd.’s portfolio, making the stock its largest holding. Ion Asset Management Ltd. owned 0.48% of Teva Pharmaceutical Industries worth $111,302,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also modified their holdings of the company. Phoenix Financial Ltd. lifted its holdings in Teva Pharmaceutical Industries by 9.4% in the third quarter. Phoenix Financial Ltd. now owns 41,295,244 shares of the company’s stock valued at $834,164,000 after acquiring an additional 3,533,800 shares during the period. National Pension Service grew its stake in shares of Teva Pharmaceutical Industries by 24.2% during the 3rd quarter. National Pension Service now owns 2,073,293 shares of the company’s stock worth $41,881,000 after purchasing an additional 404,526 shares during the period. Public Sector Pension Investment Board increased its holdings in shares of Teva Pharmaceutical Industries by 11.5% during the 3rd quarter. Public Sector Pension Investment Board now owns 670,467 shares of the company’s stock valued at $13,543,000 after purchasing an additional 69,000 shares in the last quarter. Oak Harvest Investment Services acquired a new position in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at $1,010,000. Finally, Harel Insurance Investments & Financial Services Ltd. boosted its holdings in Teva Pharmaceutical Industries by 12.9% during the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 37,696,690 shares of the company’s stock worth $761,455,000 after buying an additional 4,306,363 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Piper Sandler reaffirmed an “overweight” rating and issued a $41.00 price objective (up from $40.00) on shares of Teva Pharmaceutical Industries in a report on Wednesday, March 4th. Scotiabank raised their target price on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a “sector outperform” rating in a research report on Thursday, January 29th. Truist Financial lifted their price target on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a research note on Wednesday, February 18th. The Goldman Sachs Group increased their price target on Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. Finally, Jefferies Financial Group boosted their price objective on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $37.67.

Insider Activity at Teva Pharmaceutical Industries

In other news, insider Brian Savage sold 1,127 shares of the company’s stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $31.67, for a total transaction of $35,692.09. Following the completion of the sale, the insider owned 10,914 shares of the company’s stock, valued at $345,646.38. This represents a 9.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Placid Jover sold 14,150 shares of the firm’s stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $31.67, for a total transaction of $448,130.50. Following the completion of the transaction, the insider directly owned 6,774 shares in the company, valued at approximately $214,532.58. This represents a 67.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 948,499 shares of company stock worth $30,897,071 over the last 90 days. Corporate insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Trading Down 2.6%

TEVA stock opened at $28.54 on Monday. Teva Pharmaceutical Industries Ltd. has a 12-month low of $12.47 and a 12-month high of $37.35. The business’s 50-day moving average is $32.91 and its 200 day moving average is $26.74. The company has a current ratio of 1.04, a quick ratio of 0.80 and a debt-to-equity ratio of 1.89. The stock has a market cap of $32.81 billion, a price-to-earnings ratio of 23.78, a PEG ratio of 9.56 and a beta of 0.72.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Wednesday, January 28th. The company reported $0.96 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.31. The business had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.36 billion. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The business’s revenue was up 11.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.71 earnings per share. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. On average, sell-side analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.